These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32450807)

  • 21. Comparison of O-specific polysaccharide responses in patients following infection with
    Kaisar MH; Kelly M; Kamruzzaman M; Bhuiyan TR; Chowdhury F; Khan AI; LaRocque RC; Calderwood SB; Harris JB; Charles RC; Čížová A; Mečárová J; Korcová J; Bystrický S; Kováč P; Xu P; Qadri F; Ryan ET
    mSphere; 2023 Oct; 8(5):e0025523. PubMed ID: 37646517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissecting serotype-specific contributions to live oral cholera vaccine efficacy.
    Sit B; Fakoya B; Zhang T; Billings G; Waldor MK
    Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33558237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
    Suharyono ; Simanjuntak C; Witham N; Punjabi N; Heppner DG; Losonsky G; Totosudirjo H; Rifai AR; Clemens J; Lim YL
    Lancet; 1992 Sep; 340(8821):689-94. PubMed ID: 1355798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge.
    Tacket CO; Losonsky G; Nataro JP; Comstock L; Michalski J; Edelman R; Kaper JB; Levine MM
    J Infect Dis; 1995 Sep; 172(3):883-6. PubMed ID: 7658089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of a recombinant live oral vaccine from a non-toxigenic strain of Vibrio cholerae O1 serotype inaba biotype E1 Tor and assessment of its reactogenicity and immunogenicity in the rabbit model.
    Thungapathra M; Sharma C; Gupta N; Ghosh RK; Mukhopadhyay A; Koley H; Nair GB; Ghosh A
    Immunol Lett; 1999 Jun; 68(2-3):219-27. PubMed ID: 10424424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.
    Liang W; Wang S; Yu F; Zhang L; Qi G; Liu Y; Gao S; Kan B
    Infect Immun; 2003 Oct; 71(10):5498-504. PubMed ID: 14500467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TLP01, an mshA mutant of Vibrio cholerae O139 as vaccine candidate against cholera.
    Ledón T; Ferrán B; Pérez C; Suzarte E; Vichi J; Marrero K; Oliva R; Fando R
    Microbes Infect; 2012 Sep; 14(11):968-78. PubMed ID: 22546527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
    Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
    Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
    Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
    Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.
    Tarique AA; Kalsy A; Arifuzzaman M; Rollins SM; Charles RC; Leung DT; Harris JB; Larocque RC; Sheikh A; Bhuiyan MS; Saksena R; Clements JD; Calderwood SB; Qadri F; Kovác P; Ryan ET
    Clin Vaccine Immunol; 2012 Apr; 19(4):594-602. PubMed ID: 22357651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The oral cholera vaccine Shanchol™ when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants.
    Saha A; Khan A; Salma U; Jahan N; Bhuiyan TR; Chowdhury F; Khan AI; Khanam F; Muruganandham S; Reddy Kandukuri S; Singh Dhingra M; Clemens JD; Cravioto A; Qadri F
    Vaccine; 2016 Mar; 34(13):1551-1558. PubMed ID: 26896684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
    McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M
    Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.
    Jertborn M; Svennerholm AM; Holmgren J
    Vaccine; 1996 Oct; 14(15):1459-65. PubMed ID: 8994322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.
    Cryz SJ; Fürer E; Germanier R
    Dev Biol Stand; 1983; 53():67-72. PubMed ID: 6873478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility.
    Bishop AL; Schild S; Patimalla B; Klein B; Camilli A
    Infect Immun; 2010 Oct; 78(10):4402-20. PubMed ID: 20679439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1.
    Qadri F; Mohi G; Hossain J; Azim T; Khan AM; Salam MA; Sack RB; Albert MJ; Svennerholm AM
    Clin Diagn Lab Immunol; 1995 Nov; 2(6):685-8. PubMed ID: 8574829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial.
    McCarty JM; Lock MD; Bennett S; Hunt KM; Simon JK; Gurwith M
    Vaccine; 2019 Mar; 37(11):1389-1397. PubMed ID: 30772070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.
    Cohen MB; Giannella RA; Bean J; Taylor DN; Parker S; Hoeper A; Wowk S; Hawkins J; Kochi SK; Schiff G; Killeen KP
    Infect Immun; 2002 Apr; 70(4):1965-70. PubMed ID: 11895960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.